Business Context and Reporting Period
This Form 6-K filing by Bio Blast Pharma Ltd. (not Enlivex Ltd.) covers the month of December 2014, with a report date of December 17, 2014. The registrant is a foreign private issuer based in Tel Aviv, Israel, filing under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report consists solely of a press release regarding a patent issuance and contains no financial statements or quantitative financial data.
Material Changes
The material change reported is the issuance of a new patent by the United States Patent and Trademark Office to the registrant. No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
The filing includes no management commentary on financial guidance, outlook, risks, contingencies, or unusual items. The content is limited to the announcement of the intellectual property milestone.
Investor Verification Checklist
- Verify the specific scope and claims of the new U.S. patent referenced in Exhibit 99.1.
- Confirm the registrant's name is Bio Blast Pharma Ltd., as the input metadata incorrectly listed Enlivex Ltd.
- Review the full press release attached as Exhibit 99.1 for details on the patent's commercial potential.
- Check subsequent filings for financial impact or operational updates related to this patent.